Home›Stock Screener›AstraZeneca Pharma›Financial Statements

AstraZeneca Pharma Complete Financial Statements

12 Years of Data
2026 - 2015

In FYNone, AstraZeneca Pharma (ASTRAZEN) reported revenue ₹2,460 Cr, net profit ₹170 Cr and EPS ₹67.80, with a net profit margin of 8.2% and ROE of 21.5%. Full financial statements from FY2015 to FY2026 (12 years) — income statement, balance sheet and cash flow in ₹ Crores. Download as Excel or CSV. Compare with AstraZeneca Pharma value estimation to assess whether the stock is under or overvalued.

Complete Financial Data Export

Profitability Ratios

Net Profit Margin 8.16% 2026 data
EBITDA Margin 12.63% 2026 data
Operating Margin 12.00% 2026 data
Return on Assets 9.45% 2026 data
Return on Equity 21.53% 2026 data

Balance Sheet Ratios

Current Ratio 12.89 2026 data
Equity Ratio 43.89% 2026 data
Asset Turnover 1.16 2026 data

ASTRAZEN Revenue, Net Profit & EBITDA — Year-on-Year Growth

ASTRAZEN YoY (March 2026 vs Period) — revenue +6.8%, net profit -9.6%, EBITDA -13.7%, expenses +9.7%. For live price, earnings ratios and company overview, see AstraZeneca Pharma screener.

Revenue Growth
+6.8%
Year-over-Year
Net Profit Growth
-9.6%
Year-over-Year
EBITDA Growth
-13.7%
Year-over-Year
Expense Growth
+9.7%
Year-over-Year
Assets Growth
+31.0%
Year-over-Year
Equity Growth
+13.4%
Year-over-Year
Operating Cash Flow Growth
-123.1%
Year-over-Year
Investing Cash Flow Growth
-38.7%
Year-over-Year
Financing Cash Flow Growth
-39.4%
Year-over-Year

ASTRAZEN Income Statement — Revenue, EBITDA & Net Profit

AstraZeneca Pharma revenue ₹2,460 Cr, EBITDA ₹251 Cr, net profit ₹170 Cr, EPS ₹67.80 (None) — net profit margin 8.2%.

Periods ₹ Crores
Particulars None March 2026 March 2025 March 2024 March 2023 March 2022 March 2021 March 2020 March 2019 March 2018 March 2017 March 2016 March 2015
Revenue 2,460 2,304 1,757 1,330 1,029 820 826 845 745 583 558 571 523
Expenses 2,209 2,014 1,462 1,111 838 719 678 711 657 525 507 547 529
EBITDA 251 291 295 219 191 101 148 134 88 59 51 23 -6
Operating Profit Margin % 9.00% 12.00% 15.00% 14.00% 16.00% 11.00% 17.00% 15.00% 10.00% 8.00% 7.00% 3.00% -2.00%
Depreciation 17 29 40 15 16 17 20 19 15 15 16 17 15
Interest 6 5 2 1 1 1 1 1 0 0 0 0 0
Profit Before Tax 228 252 156 220 134 83 127 114 73 44 36 6 -21
Tax 48 65 41 58 35 21 34 42 18 18 15 1 0
Net Profit 170 188 116 162 99 62 93 72 54 26 20 5 -21
Earnings Per Share (₹) 67.80 75.01 46.30 64.60 39.70 24.60 37.30 28.90 21.80 10.40 8.00 2.10 -8.34

ASTRAZEN Balance Sheet — Assets, Liabilities & Shareholders' Equity

ASTRAZEN total assets ₹1,989 Cr, total equity ₹873 Cr, total liabilities ₹ Cr (2026) — ROE 21.5%.

Years Annual Data ₹ Crores
Particulars 2026 2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015
ASSETS
Total Assets 1,989 1,518 1,078 985 857 775 706 562 461 416 403 412
Current Assets 1,740 1,342 933 836 706 619 542 405 321 252 267 263
Fixed Assets 118 64 67 69 75 81 72 75 76 87 97 101
Capital Work in Progress 0 0 0 1 2 4 24 7 4 5 6 12
Investments 0 0 0 0 0 0 0 0 0 0 0 0
Other Assets 1,872 1,454 1,011 915 780 690 611 480 382 324 299 298
LIABILITIES
Total Liabilities
Current Liabilities 135 45 9 12 13 15 15 2 7 2 13 1
Non-Current Liabilities
SHAREHOLDERS' EQUITY
Total Equity 873 770 712 589 511 456 364 301 247 223 156 151
Share Capital 5 5 5 5 5 5 5 5 5 5 5 5
Reserves & Surplus 868 765 707 584 506 451 359 296 242 218 151 146

ASTRAZEN Cash Flow Statement — Operating, Investing & Financing

AstraZeneca Pharma operating cash flow ₹-15 Cr, investing ₹19 Cr, financing ₹-92 Cr, net cash flow ₹-88 Cr (2026).

Periods ₹ Crores
Particulars March 2026 March 2025 March 2024 March 2023 March 2022 March 2021 March 2020 March 2019 March 2018 March 2017 March 2016 March 2015
Operating Activities -15 65 28 58 101 105 87 55 9 38 57 -46
Investing Activities 19 31 22 18 5 173 -171 4 -9 0 -4 -19
Financing Activities -92 -66 -44 -25 -10 -9 -6 0 0 0 -1 0
Net Cash Flow -88 31 5 52 96 269 -90 59 -1 38 53 -64